# ATH434 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ath434

> The next catalyst for ATH434, sponsored by ALTERITY THERAPEUTICS LTD (ATHE), is its primary completion, July 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ATH434 |
| Codes | ATH434, PBT434 |
| Sponsor | ALTERITY THERAPEUTICS LTD (ATHE) https://sec-api.dev/companies/athe/catalysts |
| Indications | advanced msa, [multiple system atrophy](https://sec-api.dev/indications/multiple-system-atrophy) |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### July 17, 2024: interim data readout

- Status: completed, positive. Date confidence: exact. Indication: advanced MSA.
- First seen 2025-02-28, last confirmed 2026-08-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-018328): "17 July 2024, Alterity reported positive interim data from the ATH434-202 trial." https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm
- SEC Form 10-K (accession 0001437749-26-029135): "In July 2024, we reported positive interim data from the ATH434-202 trial in participants with advanced MSA." https://www.sec.gov/Archives/edgar/data/1131343/000143774926029135/athe20260630_20f.htm
- SEC Form 10-K (accession 0001213900-25-082027): "In July 2024, we reported positive interim data from the ATH434-202 trial in participants with advanced MSA." https://www.sec.gov/Archives/edgar/data/1131343/000121390025082027/ea0254438-20f_alterity.htm

### July 28, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: multiple system atrophy.
- First seen 2025-07-28, last confirmed 2025-07-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-067901): "- 28 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy (MSA)." https://www.sec.gov/Archives/edgar/data/1131343/000121390025067901/ea025038601ex99-1_alterity.htm

### Oct 2024: interim data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-01-24, last confirmed 2026-08-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-018328): "October 2024, Alterity announced the presentation of positive interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled "Preliminary Efficacy and Safety of ATH434 in Multiple System Atrophy" at the MDS meeting." https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-006208): "In October 2024, Alterity announced the presentation of positive interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled, "Preliminary" https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm
- SEC Form 10-K (accession 0001437749-26-029135): "In September 2024, we presented positive interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled "Preliminary Efficacy and Safety of ATH434 in Multiple System Atrophy" at the International Congress of Parkinson's Disease and Movement Disorders (MDS) meeting." https://www.sec.gov/Archives/edgar/data/1131343/000143774926029135/athe20260630_20f.htm
- SEC Form 10-K (accession 0001213900-25-082027): "In September 2024, we presented positive interim data from the ATH434-202 trial as both a late-breaking oral presentation and poster session entitled "Preliminary Efficacy and Safety of ATH434 in Multiple System Atrophy" at the MDS meeting." https://www.sec.gov/Archives/edgar/data/1131343/000121390025082027/ea0254438-20f_alterity.htm

### January 30, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-22, last confirmed 2025-08-29.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-037102): "On 30 January 2025, Alterity announced the positive topline results led by robust clinical efficacy." https://www.sec.gov/Archives/edgar/data/1131343/000121390025037102/ea024013201ex99-1_alterity.htm
- SEC Form 10-K (accession 0001213900-25-082027): "In January 2025, we announced topline results for the trial and have since published additional data supporting the positive results for ATH434 in the treatment of MSA." https://www.sec.gov/Archives/edgar/data/1131343/000121390025082027/ea0254438-20f_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-018328): "Most notably, subsequent to the end of the period, in January 2025, Alterity announced positive topline results from its lead clinical development program in early-stage Multiple System Atrophy (MSA)." https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-24-101206): "We expect the last patient visit to occur this month, which is the final milestone we need to report the topline results for this study in January of 2025." https://www.sec.gov/Archives/edgar/data/1131343/000121390024101206/ea022223401ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-006208): "The topline 12-month results from the 202 trial are expected in the first half of calendar year 2025," concluded Dr. Stamler." https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-006208): "The trial remains ongoing with topline 12-month results expected in the first half of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001013762-25-002955): "We look forward to reporting topline data from this study in mid-year 2025."" https://www.sec.gov/Archives/edgar/data/1131343/000101376225002955/ea023587401ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-018328): "30 January 2025, Alterity announced positive topline results from its ATH434-201 Phase 2 clinical trial." https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-006208): "With the achievement of this milestone, topline results remain on track to be reported by early February 2025." https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm

### Feb 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2025-01-24, last confirmed 2025-01-24.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-006208): "Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025" https://www.sec.gov/Archives/edgar/data/1131343/000121390025006208/ea022862501ex99-1_alterity.htm

### July 28, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-02-28, last confirmed 2026-08-28.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-068955): "Subsequent to the period end, on 28 July 2025, Alterity announced positive positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with MSA." https://www.sec.gov/Archives/edgar/data/1131343/000121390025068955/ea025072501ex99-1_alterity.htm
- SEC Form 10-K (accession 0001213900-25-082027): "On July 28, 2025, Alterity Therapeutics announced positive topline data form the open-label phase 2 clinical trial of ATH434 in Multiple System Atrophy." https://www.sec.gov/Archives/edgar/data/1131343/000121390025082027/ea0254438-20f_alterity.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-018328): "The trial remains ongoing with topline 12-month results expected in the second quarter of calendar year 2025." https://www.sec.gov/Archives/edgar/data/1131343/000121390025018328/ea023254702ex99-1_alterity.htm
- SEC Form 10-K (accession 0001437749-26-029135): "In July 2025, we reported positive topline data that showed ATH434 conferred a clinical benefit on areas of impairment in MSA and stabilized key biomarkers that underpin the pathology of the disease." https://www.sec.gov/Archives/edgar/data/1131343/000143774926029135/athe20260630_20f.htm
- SEC Form 10-K (accession 0001213900-25-082027): "Subsequent to the end of the period, in July 2025, we reported positive topline data that showed ATH434 conferred a clinical benefit on areas of impairment in MSA and stabilized key biomarkers that underpin the pathology of the disease." https://www.sec.gov/Archives/edgar/data/1131343/000121390025082027/ea0254438-20f_alterity.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-01-21, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-024928): ""With the Phase 3 design elements agreed upon, we are executing on our plans to initiate Phase 3 trial activities by year-end 2026."" https://www.sec.gov/Archives/edgar/data/1131343/000143774926024928/ex_995835.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-022859): "With the Phase 3 design elements confirmed, we are finalizing the protocol and remain on track to initiate Phase 3 trial activities by year-end 2026."" https://www.sec.gov/Archives/edgar/data/1131343/000143774926022859/ex_985272.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015992): "Alterity remains on track to hold its End-of-Phase 2 meeting with the FDA in mid-2026, the next key step toward initiation of a pivotal Phase 3 trial in MSA." https://www.sec.gov/Archives/edgar/data/1131343/000143774926015992/ex_960223.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-005889): "A key milestone during the year will be our End-of-Phase 2 meeting with the FDA in mid-2026, which represents the final regulatory step before initiating our pivotal, Phase 3 study." https://www.sec.gov/Archives/edgar/data/1131343/000121390026005889/ea027349001ex99-1_alterity.htm

### July 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Multiple System Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." https://clinicaltrials.gov/study/NCT07729852

### Jul to Oct 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Multiple System Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." https://clinicaltrials.gov/study/NCT07729852

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ath434.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATH434 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ath434

```bibtex
@misc{secapidev_pdufa_ath434_20261116,
  title        = {ATH434 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ath434}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ath434_20261116","title":"ATH434 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ath434","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
